Literature DB >> 16128586

High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I.

Leonid Gaidukov1, Dan S Tawfik.   

Abstract

Serum paraoxonase (PON1) is a high-density lipoprotein (HDL)-associated enzyme exhibiting antiatherogenic properties. This study examined the interaction of recombinant PON1 with reconstituted HDL comprised of PC, cholesterol, and various apolipoproteins (apoA-I, -II, and -IV). The affinity, stability, and lactonase activity were strongly correlated, with apoA-I exhibiting the strongest effects, apoA-IV exhibiting weaker yet significant effects, and apoA-II having a negative effect relative to protein-free particles. We found that PON1 binds apoA-I HDL with sub-nanomolar affinities (K(d) << 10(-)(9) M) and slow dissociation rates (t(1/2) > 80 min), while binding affinity for other particles was dramatically lower. A truncated form of PON1 lacking the N-terminal helix maintains considerable binding to apoA-I HDL (K(d) = 1.2 x 10(-)(7) M), validating the structural model which indicates additional parts of the enzyme involved in HDL binding. Kinetic inactivation assays revealed the existence of an equilibrium between two forms of PON1 differing in their stability by a factor of 100. Various lipoproteins and detergent preparations shift this equilibrium toward the more stable conformation. Consistent with its highest affinity, only apoA-I HDL is capable of totally shifting the equilibrium toward the stable form. The paraoxonase and arylesterase activities were stimulated by HDL by 2-5-fold as previously reported, almost independently of the apoliporotein content. In contrast, only apoA-I is capable of stimulating the lactonase activity by <or=20-fold to k(cat)/K(M) values of 10(6)-10(7) M(-)(1) s(-)(1), while apoA-IV and apoA-II have almost no effect. Overall, the results indicate the high stability, selectivity, and catalytic proficiency of PON1 when anchored onto apoA-I HDL, toward lactone substrates, and lipophilic lactones in particular.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16128586     DOI: 10.1021/bi050862i

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  55 in total

1.  Regulation of paraoxonase 1 (PON1) in PCB 126-exposed male Sprague Dawley rats.

Authors:  Hua Shen; Larry W Robertson; Gabriele Ludewig
Journal:  Toxicol Lett       Date:  2012-01-12       Impact factor: 4.372

2.  Differential effect of lysophospholipids on activities of human plasma paraoxonase1, either soluble or lipid-bound.

Authors:  Cheon Ho Park; Su Duy Nguyen; Mee Ree Kim; Tae-Sook Jeong; Dai-Eun Sok
Journal:  Lipids       Date:  2006-04       Impact factor: 1.880

3.  Cholesterol-Independent Suppression of Lymphocyte Activation, Autoimmunity, and Glomerulonephritis by Apolipoprotein A-I in Normocholesterolemic Lupus-Prone Mice.

Authors:  Leland L Black; Roshni Srivastava; Trenton R Schoeb; Ray D Moore; Stephen Barnes; Janusz H Kabarowski
Journal:  J Immunol       Date:  2015-10-14       Impact factor: 5.422

4.  Dominant role of paraoxonases in inactivation of the Pseudomonas aeruginosa quorum-sensing signal N-(3-oxododecanoyl)-L-homoserine lactone.

Authors:  John F Teiber; Sven Horke; Donovan C Haines; Puneet K Chowdhary; Junhui Xiao; Gerald L Kramer; Robert W Haley; Dragomir I Draganov
Journal:  Infect Immun       Date:  2008-03-17       Impact factor: 3.441

5.  A high throughput serum paraoxonase assay for discovery of small molecule modulators of PON1 activity.

Authors:  Tiffany L Graves; John E Scott
Journal:  Curr Chem Genomics       Date:  2008-11-26

6.  Molecular dynamics simulation of human serum paraoxonase 1 in DPPC bilayer reveals a critical role of transmembrane helix H1 for HDL association.

Authors:  Mahesh Chandra Patra; Surya Narayan Rath; Sukanta Kumar Pradhan; Jitendra Maharana; Sachinandan De
Journal:  Eur Biophys J       Date:  2013-12-03       Impact factor: 1.733

7.  Decreased paraoxonase activity in critically ill patients with sepsis.

Authors:  Frantisek Novak; Lucie Vavrova; Jana Kodydkova; Frantisek Novak; Magdalena Hynkova; Ales Zak; Olga Novakova
Journal:  Clin Exp Med       Date:  2009-09-04       Impact factor: 3.984

8.  Nitro-Oleic Acid Reduces J774A.1 Macrophage Oxidative Status and Triglyceride Mass: Involvement of Paraoxonase2 and Triglyceride Metabolizing Enzymes.

Authors:  Mira Rosenblat; Oren Rom; Nina Volkova; Michael Aviram
Journal:  Lipids       Date:  2016-06-25       Impact factor: 1.880

9.  Surface plasmon resonance analysis of the mechanism of binding of apoA-I to high density lipoprotein particles.

Authors:  Sissel Lund-Katz; David Nguyen; Padmaja Dhanasekaran; Momoe Kono; Margaret Nickel; Hiroyuki Saito; Michael C Phillips
Journal:  J Lipid Res       Date:  2009-09-28       Impact factor: 5.922

10.  In vivo administration of BL-3050: highly stable engineered PON1-HDL complexes.

Authors:  Leonid Gaidukov; Dganit Bar; Shiri Yacobson; Esmira Naftali; Olga Kaufman; Rinat Tabakman; Dan S Tawfik; Etgar Levy-Nissenbaum
Journal:  BMC Clin Pharmacol       Date:  2009-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.